16
Jun
2026

Kinhoo Pharmaceutical Co., Ltd.

Exhibitor at CPHI & PMEC China 2026 stand E10B25, Pharma Ingredients
About Us

Kinhoo Pharmaceutical Co., Ltd., stock code: 831186, as a NEEQ listed enterprise, found in April 2005 with a registered capital of RMB 65.6 million. Kinhoo is a modernized pharmaceutical enterprise integrating pharmaceutical R&D, production and sales, engaged with medical intermediates, active pharmaceutical ingredients (APIs) and pharmaceutical preparations. To meet health needs of patients, Kinhoo holds the business philosophy of “Perfection, Diligence, Concision”, and strives for building an international brand pharmaceutical enterprise. Kinhoo has two Manufacturing Sites, Golden Coast bio-industrial park and Dingjia Bay international medical ecological park, covering an area of 31,670 m2 and 53,450 m2 respectively. Kinhoo have 13 workshops with 25 production lines and 30 patents. Kinhoo maintains high standards of Quality Management in the development, manufacture and control of medicinal products. All medicinal products are assessed by the competent authority to get marketing authorizations, the manufacture of medicinal products has strictly taken place in accordance with guidelines for current Good Manufacturing Practice, to ensure compliance with contemporary requirements of safety, quality and efficacy.

  • Country/Region:
    China
  • On CPHI since:
    2017
  • Employees:
    500 - 999
Company types
Pharmaceutical company
Contact info
Event information
CPHI & PMEC China 2026
  • 16 Jun 2026 - 18 Jun 2026
  • Shanghai New International Expo Center
  • Visit us at stand E10B25, Pharma Ingredients

Products Featured at CPHI & PMEC China 2026

  • Sorafenib tosylate

    Product Sorafenib tosylate

    Sorafenib tosylate (CAS No.: 475207-59-1) Indications: For the treatment of patients with advanced renal cell carcinoma (RCC). For the treatment of patients with unresectable hepatocellular carcinoma (HCC). For the treatment of patients with locally recurrent or metastatic, progressive, differentia...
  • Vardenafil hydrochloride

    Product Vardenafil hydrochloride

    Vardenafil hydrochloride (CAS No.: 330808-88-3)Indications: For the treatment of erectile dysfunction.

  • Lenvatinib mesylate

    Product Lenvatinib mesylate

    Lenvatinib mesylate (CAS No.: 857890-39-2)Indications: For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid carcinoma (D...
  • Ibuprofen arginine

    Product Ibuprofen arginine

    Ibuprofen arginine (CAS No.: 57469-82-6)Indications: For relief of toothache, dysmenorrhea, pain caused by injury (e.g., athletic injuries), joint and ligament pain, back pain, headache, and fever caused by influenza.

  • Ferrous succinate

    Product Ferrous succinate

    Indications: For the prevention and treatment of Iron Deficiency Anemia (IDA).